NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. The Company offers services, such as Mitochondrial Replacement Therapy In Reproductive, Intrauterine Insemination (IUI), Mitochondrial replacement therapy (MRT) techniques, In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI), semen analysis, testicular / epididymal sperm aspiration or extraction / percutaneous epididymal sperm aspiration, embryo transfer, chromosome screening and egg freezing. The Company’s clinics are located in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. MRT involves an additional egg from a third person, and manipulating both the recipient egg and the donor egg.
Ticker SymbolNIVFW
Company nameNewGenIvf Group Ltd
IPO dateFeb 15, 2022
CEOMr. Claudius Tsang
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
AddressLevel 39, Marina Bay Financial Centre
City
Stock exchangeNASDAQ Capital Market Consolidated
CountrySingapore
Postal code018983
Phone6568185796
Websitehttps://newgenivf.com/
Ticker SymbolNIVFW
IPO dateFeb 15, 2022
CEOMr. Claudius Tsang
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data